United States Food and Drug Administration (FDA) has declined to approve Amylin’s Diabetes drug “Bydureon” as more tests were expected to be run on the drug, revealed the drugs company Amylin Pharmaceuticals in a statement. The FDA has decided that it would like to run a QT test to know how the drug affects patients’ heart rate.
The Food and Drug Administration has requested the results of a study which would evaluate the efficiency and safety of the drug. According to the company that has produced the Diabetes drug, it is aiming to respond to the FDA’s requests by the end of next year. Hence, only when the company’s response comes, it can be said that whether the drug will be approved or not.
No comments:
Post a Comment